The purpose of this study was to examine the efficacy of cognitive behavioral therapy (CBT) for anxiety-related disorders based on randomized placebo-controlled trials. We included 41 studies that randomly assigned patients (N = 2,843) with acute stress disorder, generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), panic disorder (PD), posttraumatic stress disorder (PTSD), or social anxiety disorder (SAD) to CBT or a psychological or pill placebo condition.
, generalized anxiety disorder (GAD; Cuijpers et al., 2014) , social anxiety disorder (SAD; Mayo-Wilson et al., 2014) , obsessivecompulsive disorder (OCD; Öst, Havnen, Hansen, & Kvale, 2015) , panic disorder (PD; Pompoli et al., 2016) , as well as anxiety disorders globally (Bandelow et al., 2015; Cuijpers, Cristea, Weitz, Gentili, & Berking, 2016; Watts, Turnell, Kladnitski, Newby, & Andrews, 2015) . However, these meta-analyses examined the effect of CBT relative to a heterogeneous set of control conditions, most frequently consisting of a waitlist control or treatment-as-usual (TAU). Such comparisons are suboptimal because waitlist control conditions do not control for the effect of patient expectations on treatment outcomes (e.g., Greenberg, Constantino, & Bruce, 2006) , and TAU conditions are highly varied and not closely monitored (Watts et al., 2015) .
The gold-standard study design to best estimate the effect of a treatment is a randomized controlled trial (RCT) using a psychological or pill placebo as a comparison, as such a control can be standardized within a study and better accounts for the effect of patient expectations on symptom improvement. Comparing CBT to placebo also provides a more useful estimate of the effect of CBT for providers who may be considering medication as a treatment option, as it is standard practice in medication trials to use a placebo comparator to examine the treatment efficacy. In fact, the US Food and Drug Administration will not accept noninferiority studies with active comparators for approval of new drugs, still considering placebo-controlled RCTs as the only effective method for determining efficacy (Feifel, 2009; Laughren, 2001 ).
In 2008, some of us (Hofmann & Smits, 2008) published the only meta-analysis of exclusively randomized placebo-controlled trials of CBT for anxiety and related disorders. We identified 27 studies showing moderate to large effects (Hedges' g = 0.73) of CBT for anxiety symptoms and moderate effects (Hedges' g = 0.45) for depressive symptoms in completer samples. Effects varied across disorders, with the strongest effect sizes found in OCD and acute stress disorder, and the weakest in PD. Of note, a meta-analysis by Cuijpers, Cristea, Karyotaki, Reijnders, and Huibers (2016) examined the effects of CBT for PD, OCD, and SAD compared to pill placebo in addition to waitlist and TAU. However, this analysis did not include studies that compared CBT to a psychological placebo (e.g., supportive counseling), which is an important comparison condition because it can serve as a control for so-called common factors that can impact treatment outcome, such as the therapeutic alliance (Horvath, Del Re, Flückiger, & Symonds, 2011; Smits & Hofmann, 2009 ).
The present study sought to update the analysis by Hofmann and Smits (2008) with data from randomized placebo-controlled trials of CBT for anxiety-related disorders published since 2008. Such an upto-date analysis of the efficacy of CBT is necessary to further inform ongoing debate about the efficacy of different treatment modalities (e.g., Hofmann & Curtiss, 2015; Wampold & Imel, 2015) , and to provide evidence for researchers and policy makers about the potential utility of disseminating CBT interventions. This update to Hofmann and Smits (2008) also provides a more comprehensive assessment of the scope by CBT's impact on anxiety by including additional moderator analyses, outcome variables, and an examination of follow-up data. Although OCD, acute stress disorder, and PTSD are no longer classified as anxiety disorders in DSM-5, we included them in the present study to be consistent with the prior analysis, and because of the high degree of overlap in the etiology and treatment of these disorders when compared to DSM-5 anxiety disorders (Stein et al., 2010; Zoellner, Rothbaum, & Feeny, 2011) .
Similar to Hofmann and Smits (2008) , we investigated betweengroup effect sizes for continuous measures of anxiety and depression symptoms at posttreatment, as well as categorical indices of response rates and dropout rates. We also examined the effects of CBT on target disorder symptom measures (as opposed to general indices of anxiety) and QOL measures at posttreatment, as well as long-term follow-up outcomes. In addition to study year, placebo type, number of treatment sessions, and use of a completer versus intent-to-treat (ITT) analyses (moderators tested by Hofmann & Smits, 2008) , we examined sample characteristics (race, sex, sample size, inclusion of patients on medication), risk of bias, and treatment type (behavioral, cognitive or both; group vs. individual) as moderators of treatment outcome.
METHODS
Following the guidelines set forth in the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, the protocol for this meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42016050841).
Selection of studies
To identify eligible studies, we searched PubMed and PsycINFO for articles published from the first available date to January 4, 2017. The following search terms were used: ((random*)) AND (((cognitive behavior*therap*) OR (cognitive therap*) OR (behavior*therap*))) AND ((GAD)
OR (acute stress disorder))). In addition, we conducted manual searches of reference lists from recently published meta-analyses and review articles. Our search produced 3,215 unique studies, the first 1,165 of which were reviewed for eligibility in Hofmann and Smits (2008) using the same eligibility criteria.
Studies were selected by the first, second, and third authors and a team of independent trained assessors. Studies were included in the present meta-analysis if (1) patients were between ages 18 and 65 and met DSM-III-R, DSM-IV, or DSM-5 diagnostic criteria for acute stress disorder, GAD, OCD, PTSD, SAD, or specific phobia as determined by a psychometrically sound and structured diagnostic instrument; (2) patients were randomly assigned to either CBT or placebo (pill or psychological). A psychological placebo was defined as a condition involving interventions to control for nonspecific factors (e.g., contact with a therapist equivalent to the active treatment, reasonable rationale for the intervention, discussion of the psychological problem), and consisting only of treatment elements without demonstrated efficacy for the condition being treated (e.g., relaxation for OCD or PTSD; Smits & Hofmann, 2009) ; (3) the clinical severity of the anxiety disorder was assessed by means of psychometrically sound measures; and (4) studies provided sufficient data to calculate effect sizes.
Studies were excluded if (1) they consisted of secondary analyses of a larger, more complete, or earlier study; (2) placebo interventions included active treatment ingredients for the target problem (e.g., self-guided exposures); (3) the CBT intervention was deemed to be "third-wave" (Acceptance and Commitment Therapy, mindfulnessbased interventions, etc.); (4) the entire study sample had a particular comorbidity (e.g., substance abuse or a medical condition); or (5) the intervention took place remotely (over the phone or computer; see Olthuis, Watt, Bailey, Hayden, and Stewart (2015) for a meta-analysis on Internet-based CBT for anxiety).
Data extraction
For each study, the first, second, and third authors independently identified the outcome measures to be used for the analysis. This included continuous measures of disorder specific symptoms, other anxiety symptoms, depression, and QOL, as well as dichotomous outcomes of treatment response and dropout percentage. For those studies that reported multiple indices of treatment response, we selected the most conservative measure. Data were then extracted for the CBT and placebo treatment arms at pretreatment, posttreatment, and if reported, 6-month follow-up (or closest available). If data necessary for calculating effect sizes were not available in the published manuscript, we contacted the authors. We also extracted data on sample and study characteristics, including sample size, demographics, placebo type, CBT treatment type (exposure, cognitive, or both; group vs. individual), number of sessions, type of analysis (completer vs. ITT), and year of publication. Data were extracted on two separate occasions by independent raters and compared to ensure accuracy, with discrepancies resolved by the first and second authors.
Risk of bias assessment
We assessed study quality with the Cochrane Collaboration's tool for assessing risk of bias (Higgins & Altman, 2008) . This tool involves assessing each study as containing a high, low, or unclear level of bias risk in a number of domains: (1) Sequence Generation: Was allocation of participants to treatment condition adequately generated in a random manner? (2) Allocation Concealment: Was treatment assignment adequately concealed from investigators and participants prior to randomization? (3) Blinding: Were outcome assessors, therapists, and patients (when possible) blind to the treatment patients were receiving? (4) Incomplete Outcome Data: Were outcome data missing at random and imputed using appropriate methods? (5) Selective Outcome Reporting: Were prespecified outcome variables of interest adequately and completely reported? A total bias assessment was created for each study by assigning a value of 0 (low bias risk), 1 (unclear bias risk), or 2 (high bias risk), and summing the score of each category.
The first and second authors independently rated each study and then met to resolve any discrepancies. Interrater reliability for the total bias assessment was strong (Cronbach's = .81).
Quantitative data synthesis
We examined heterogeneity in our data using the chi-squared test and the I 2 statistic, which is an indicator of the strength of the heterogeneity. Guidelines for I 2 suggest that 25, 50, and 75% values represent low, moderate, and high heterogeneity, respectively (Higgins, Thompson, Deeks, & Altman, 2003) . Regardless of statistical heterogeneity, we used a random effects model because of the variability within patient and methodological characteristics of the included studies. For continuous outcomes, between-groups effect sizes and their 95% confidence intervals (CI) were calculated using Hedges' g (Hedges & Olkin, 1985) .
When a study used multiple measures in a given outcome category, effect sizes were averaged across all outcome measures in the category. Effect sizes were calculated using either pre-and posttreatment means and standard deviations (SDs) or the mean and SD of pre-post change scores. For follow-up effect sizes, 6-month (or closest available) follow-up means and SDs were used in place of posttreatment data.
For categorical outcomes (i.e., response rates and attrition), we calculated the odds ratio (OR) and CI using the Cox-Hinkley-MiettinenNurminen method (Miettinen & Nurminen, 1985) . To calculate ORs, we used the number of treatment responders and patients randomized to each condition, or if necessary we calculated number of responders based on the response rate reported. To investigate potential moderator effects on outcome, we used the between-group heterogeneity statistic (Q B ) recommended by Hedges and Olkin (1985) for categorical moderators and metaregression procedures for continuous moderators.
To examine the potential influence of publication bias, we inspected the funnel plot to evaluate asymmetry of effect size estimates as a function of their precision. We used Egger's regression intercept as a formal test of funnel plot asymmetry (Egger, Smith, Schneider, & Minder, 1997) . In addition, the Trim and Fill method (Duval & Tweedie, 2000) was used, which estimates the number of studies that would have to be removed from the funnel plot to make it symmetrical, and then imputes an estimated effect size that accounts for funnel plot asymmetry. All meta-analytic procedures were conducted in Comprehensive Meta-Analysis, Version 3.
RESULTS

Study flow and characteristics
The flow diagram in Figure 1 shows the number of studies excluded and the reasons for exclusion at each stage of study selection. The final analysis included 41 studies, 16 of which were not included in the Hofmann and Smits (2008) paper. Together these studies examined a total of 2,843 patients randomized to either CBT or placebo.
Of the 41 studies included in the analysis, 40 reported continuous outcome data for target disorder symptoms, and 33 reported categorical outcome data on response rates. PTSD was the most commonly represented disorder (14 studies comprising 1,252 patients), followed by SAD (12 studies, 753 patients), PD (five studies, 328 patients), OCD (four studies, 313 patients), acute stress disorder (four studies, 140 F I G U R E 1 Flow diagram of study selection process patients), and GAD (two studies, 57 patients). Most studies (n = 29) compared CBT to a psychological placebo, with supportive counseling being the most common comparison treatment. The majority of CBT treatments used both formal therapist-guided exposure and cognitive techniques (n = 24), though some treatments consisted of primarily exposure techniques (n = 10) or primarily cognitive strategies (n = 7). Thirty-four studies examined individual CBT, while seven studies examined group CBT. Mean treatment duration across studies was 11.0 sessions (SD = 4.72). The average study sample had a mean age of 36.0 years (SD = 6.53), of which 58.9% was female (SD = 21.21) and 73.0% was white (SD = 21.87). Of the 35 studies that included information about psychiatric medication use, 18 studies excluded patients receiving psychiatric medication, 15 studies included patients who were on stable doses, and two studies excluded only specific medications (e.g., benzodiazepines, selective serotonin reuptake inhibitors).
From the latter two groups, nine studies reported data on the number of patients taking psychiatric medication. On average, 34.2% of those samples (SD = 17.4) received psychiatric medication. In terms of risk of bias, all but one study had a rating of unclear risk of bias in at least one of the five categories, and 14 of the 40 studies had at least one category of high risk. The number of studies with low, unclear, and high risk of bias in each of the categories was as follows: sequence generation (15 low, 26 unclear, 0 high), allocation concealment (14 low, 27 unclear, 0 high), blinding (27 low, 11 unclear, 3 high), incomplete outcome data (9 low, 19 unclear, 13 high), and selective outcome reporting (37 low, 4 unclear, 0 high). Sixteen studies used ITT analyses for the continuous outcomes, while 25 only presented completer data. Information about characteristics of each study can be seen in the Supporting Information Table S1 .
Data synthesis
Dropout rates
Examination of dropout rates showed a significantly greater likelihood of dropout in CBT compared to placebo (OR = 1.35, 95% CI = 1.05-1.77, P < .05). The weighted mean dropout rate across all studies was 24.0% in CBT and 17.2% in placebo. This difference in dropout rates was largely due to a greater attrition rate in the 14 studies examining PTSD (29.0% in CBT vs. 17.2% in placebo), which had an OR of 1.82 (95% CI = 1.32-2.52, P < .01). With PTSD studies removed, the difference in dropout between CBT (19.6%) and placebo (17.2%) reduced to nonsignificance (OR = 1.10, 95% CI = 0.78-1.55, P = n.s.).
Outcomes after acute treatment
Between-group effect sizes for continuous measures of target disorder symptoms from pre-to posttreatment were in the medium range Heterogeneity was in moderate range for disorder-specific outcomes (Q = 83.39, df(Q) = 38, P < .001; I 2 = 54.43%) and QOL (Q = 30.81, df(Q) = 15, P < .05; I 2 = 51.31%), small for other anxiety symptoms (Q = 34.63, df(Q) = 25, P < 0.10; I 2 = 27.80%), and nonsignificant for depression symptoms (Q = 19.31, df(Q) = 25, P = n.s.;
I 2 = 0.00%). For categorical outcomes, heterogeneity was also in the moderate range (Q = 73.25, df(Q) = 32, P < .01; I 2 = 56.32%).
Long-term follow-up
Twenty-two of the 41 studies included in the analysis reported on follow-up outcomes. The mean follow-up assessment period was 5.55 months (SD = 2.37). The effect size for target disorder symptoms at follow-up was in the moderate range (Hedges' g = 0.47, 95% CI = 0.30-0.64, P < .0001), as was the effect size for other anxiety symptoms (Hedges' g = 0.42, 95% CI = 0.23-0.62, P < .0001). Fourteen studies reported follow-up data for depression, producing a Hedges' g of 0.29 (95% CI = 0.16-0.42, P < .0001). Only eight studies reported QOL data at follow-up (all but one of which were PTSD studies), producing a statistically significant but minimal effect (Hedges' g = 0.15, 95% CI = 0.01-0.28, P < .05).
Publication bias
Based on the funnel plot for the disorder-specific symptom measures, Egger's regression intercept was 2.25 (P < .001), suggesting asymmetry in the funnel plot. Using the Trim and Fill method, 14 studies would have to be trimmed from the right side of the mean to make the plot symmetrical, leading to an adjusted effect size of 0.33 (95% CI = 0.19-0.48).
Comparisons between diagnostic groups
Effect sizes and 95% CI for diagnosis-specific symptoms, anxiety, depression, and QOL for different diagnostic groups are presented in Figure 4 . Results revealed significant differences in controlled effect sizes for target disorder symptom measures across disorders (Q B = 12.52, df = 5, P < .05).
Greatest effects were seen in OCD (Hedges' g = 1.13, 95% CI = 0.58-1.68, P < .001), followed by GAD (Hedges' g = 1.01, 95% CI = 0.44-1.57, P < .001) and acute stress disorder (Hedges' g = 0.87, 95% CI = 0.32-1.41, P < .01). SAD (Hedges' g = 0.41, 95% CI = 0.25-0.57, P < .0001), PTSD (Hedges' g = 0.48, 95% CI = 0.26-0.71, P < .0001), and PD (Hedges' g = 0.39, 95% CI = 0.12-0.65, P < .0001) each produced effect sizes in the small to medium range (see Figure 4 ).
Pairwise comparisons showed OCD studies to be associated with significantly greater effect sizes than PTSD, SAD, and PD studies (all P values < .05). GAD studies exhibited significantly greater effect sizes than PTSD studies (P < .05). To examine whether differential effect sizes across disorders may have been related to varying strength of placebo conditions for different conditions, we examined uncontrolled pre-post effect sizes of just placebo conditions. Results showed no difference in within-group effect sizes across different disorders during placebo treatment (Q B = 3.34, df = 5, P = n.s.; Hedges' g = 0.38-0.55), a finding that did not change when examining pill (Q B = 4.79, df = 3, P = n.s.) and psychological placebos (Q B = 3.34, df = 5, P = n.s.)
separately.
When examining categorical outcomes, results similarly showed significant differences across disorders (Q B = 13.16, df = 5, P < .05).
ORs and 95% CI by disorder type are presented in Figure 5 . Pairwise comparisons showed greater ORs in OCD compared to PTSD (Q B = 8.90, df = 1, P < .01) and PD (Q B = 5.39, df = 1, P < .05).
Moderator analyses
Moderator analyses are reported for target disorder symptom out- Sample characteristics, including race (B = 0.01, SE = 0.00, P = n.s.), sex (B = 0.00, SE = 0.00, P = n.s.), sample size (B = 0.00, SE = 0.00, P = n.s.), and inclusion of patients receiving medication (Q B = 0.25, df = 1, P = n.s.) did not moderate effect sizes. In addition, study characteristics, such as number of sessions (B = −0.01, SE = 0.02, P = n.s.), study year (B = 0.00, SE = 0.01, P = n.s.), and risk of bias (B = −0.05, SE = 0.05, P = n.s.), were not found to relate to effect sizes.
F I G U R E 3
Odds ratios (OR) and 95% confidence intervals (CI) for responder status following acute CBT compared to placebo. ASD, acute stress disorder; GAD, generalized anxiety disorder; OCD, obsessive compulsive disorder; PD, panic disorder; PTSD, posttraumatic stress disorder; SAD, social anxiety disorder; CIDI, composite international diagnostic interview PTSD module; CAPS, clinician administered PTSD scale; CGI-S, clinical global impressions scale-severity; CGI-I, clinical global impressions scale-improvement; SRT, symptom rating test; CSC, clinically significant change (see Foa, Rothbaum, Riggs, & Murdock, 1991; Lucas, 1994; Sharp et al., 1996) ; PCLS, PTSD checklist; SRQ-20, self-reporting questionnaire; SPDS-S, social phobic disorder-severity form; SPDS-C, social phobic disorder-change form; FNE, fear of negative evaluation scale; SIAS, social interaction anxiety scale; CIC-SP, clinical impression of change-social phobia scale; LSAS-SR, Liebowitz social anxiety scale
DISCUSSION
Given that patient expectations for improvement alone can lead to significant symptom change (Greenberg et al., 2006; Wampold, Minami, Tierney, Baskin, & Bhati, 2005) , the most rigorous method to estimate the effect of an intervention such as CBT is to compare it to a placebo condition. Accordingly, the present study sought to assess the state of the evidence for CBT for anxiety and related disorders by conducting a meta-analysis specifically on randomized placebo-controlled trials. Building on a previous meta-analysis by our group (Hofmann & Smits, 2008) , this review yielded 16 additional studies (a 59% increase), examining a total of 41 trials with 2,843 patients who were randomly assigned to CBT or placebo for acute stress disorder, GAD, OCD, PD, PTSD, or SAD. Results yielded significant but moderate effect sizes at posttreatment and follow-up for target disorder symptoms, and significantly greater odds of treatment response for CBT than placebo. In addition, CBT was associated with significant effects on other anxiety measures, depression, and QOL. These findings show that CBT is associated with significantly greater benefit for anxiety-related disorders than placebo conditions, and that the superior effects of CBT extend beyond symptoms of the disorder being treated.
The present meta-analytic review extends the work of Hofmann and Smits (2008) and other previous meta-analyses in several important ways. For one, the present study included sufficient studies with F I G U R E 4 Placebo-controlled effect sizes and 95% confidence intervals (CI) for disorder-specific, anxiety, depression, and quality of life measures. QOL, quality of life; ASD, acute stress disorder; GAD, generalized anxiety disorder; OCD, obsessive compulsive disorder; PD, panic disorder; PTSD, posttraumatic stress disorder; SAD, social anxiety disorder F I G U R E 5 Odds ratios and 95% confidence intervals (CI) of treatment response for CBT compared by target disorder. QOL, quality of life; ASD, acute stress disorder; GAD, generalized anxiety disorder; OCD, obsessive compulsive disorder; PD, panic disorder; PTSD, posttraumatic stress disorder; SAD, social anxiety disorder follow-up data to examine whether gains during CBT were maintained after treatment concluded. Results showed follow-up effect sizes equivalent to posttreatment for disorder-specific symptoms, anxiety, and depression. This maintenance of gains in response to CBT compared to placebo is of great importance given that the goal of psychological treatment is not just to provide immediate relief of symptoms, but to produce long-lasting change in patients' lives. This finding is also important because meta-analyses relying on waitlist controlled trials are not able to examine controlled followed-up data, since treatment cannot be ethically withheld past the active treatment period for patients assigned to a waitlist.
The larger sample size in the present study also allowed us to conduct more robust moderator analyses on a wider array of variables.
Effect size was not found to related to risk of bias, publication year, or the majority of sample characteristics (race, age, sex, sample size, medication use) and treatment characteristics (number of sessions, placebo type), but the effect of group versus individual treatment was significant. Although group CBT was only tested in PTSD and SAD studies, effect sizes were smaller for group treatment compared to individual CBT for those disorders. This finding is consistent with direct comparisons between group and individual treatments in SAD (e.g., Hedman et al., 2013) . Moreover, treatments that primarily focused on exposure techniques produced larger effect sizes (Hedges' g = 0.78) than those that included both cognitive and behavioral techniques (Hedges' g = 0.53) and cognitive techniques alone (Hedges' g = 0.38), though these differences were not statistically significant. This is inconsistent with an earlier head-to-head comparison that led the author to conclude that exposure and cognitive treatments tend to be equally effective (Ougrin, 2011) ; however, this interpretation was based on comparisons of relatively small numbers of trials and therefore may be biased.
A number of our results mirror those found in the previous analysis by Hofmann and Smits (2008) and other prior research. Specifically, the strength of the effect of CBT depended on whether the analysis was conducted on completer or ITT samples, with completer samples producing significantly larger effect sizes, though not ORs, compared to ITT samples. Such a discrepancy between ITT and completer samples is particularly important given that CBT was associated with significantly greater dropout rates than placebo in the present analysis, a result not found in Hofmann and Smits (2008) . Notably, this result appeared to be driven by greater dropout rates among CBT patients in PTSD studies, which has also been found in previous meta-analytic research (Imel, Laska, Jakupcak, & Simpson, 2013) . Such a finding suggests that for PTSD studies, the superior effect of CBT compared to placebo may be inflated by lack of data from dropouts.
Dropout rates in CBT for non-PTSD studies (19.6%), on the other hand, were not significantly different from placebo, which is consistent with prior research comparing dropout rates between CBT and other treatments (e.g., Ong, Clyde, Bluett, Levin, & Twohig, 2016) . Furthermore, our analysis of dropout in non-PTSD studies produced an identical dropout rate as another meta-analysis examining CBT for anxiety disorders in a different set of studies (Fernandez, Salem, Swift, & Ramtahal, 2015) . We can also compare our effect size results with a Also similar to the findings of Hofmann and Smits (2008) , CBT effect sizes varied across disorders, with large effect sizes for OCD and acute stress disorder studies and small to moderate effect sizes for PTSD, SAD, and PD. In contrast to previous results, GAD studies were associated with large effect sizes, which were significantly greater than PTSD and SAD studies. Effects for OCD studies were also significantly greater than PTSD, SAD, and PD. Previous studies have reported a relatively small effect of pill placebo in OCD, and a large placebo response for PD, PTSD, and GAD (Khan et al., 2005; Sugarman, Kirsch, & Huppert, 2017) , which could plausibly account for differential efficacy across disorders. In the present study, however, we did not find any effect of psychological disorder on pre-post effect sizes of placebo, even when examining pill and psychological placebo separately. Nonetheless, given the relatively small number of studies examining each disorder, findings regarding both the absence of differential placebo efficacy and the superior effects of OCD and GAD should be interpreted with caution.
Highlighting the importance of comparing CBT to placebo controls, effect sizes in the present analysis were substantially smaller than previous meta-analyses comparing the effect of CBT to waitlist or other control treatments for disorder-specific symptoms (Bandelow et al., 2015) , depression , and QOL (Hofmann, Wu, & Boettcher, 2014) in anxiety disorder samples. For instance, the metaanalysis by Bandelow et al. (2015) comparing CBT to waitlist produced an overall effect size of 1.23 for anxiety disorder symptoms. In contrast, we observed that CBT was associated with an effect size of 0.56 when compared to placebo. Given that placebo controls are better able to account for nonspecific factors of a treatment, such as expectancy effects, the more conservative estimates found in the present study are likely to be the more accurate reflection of the specific effect of CBT. Using only placebo-controlled trials also allows for a more meaningful comparison to effect sizes reported in medication trials. The meta-analysis by Bandelow et al. (2015) , for instance, found pharmacotherapy for GAD, PD, and SAD to be associated with pooled placebocontrolled effect sizes ranging from 0.17 to 0.96 (M = 0.58, SD = 0.22) depending on the medication, suggesting similar efficacy.
A number of limitations should be noted regarding the present research. First, only 16 of the 41 studies included used ITT analyses, and the use of completer analyses appeared to lead to greater effect size estimates. Even among studies using ITT analyses, results from our risk of bias assessment indicated that many studies did not account for missing data properly, or did not provide adequate information for why data were missing or how missing data were dealt with. Relatedly, the present results may have been influenced by publication bias. In addition, criteria for treatment response varied between studies, potentially contributed to increased heterogeneity in the effect sizes for categorical outcomes.
Another limitation is that apart from studies examining PTSD, samples were not particularly diverse racially. The mean sample of non-PTSD studies was 82% white, with only two non-PTSD studies using a sample with more than 23% non-whites. Future research is needed to examine the generalizability of the present results to more diverse samples. Finally, it should be noted that there was some degree of heterogeneity in the types of placebo conditions used across studies.
Although no difference between studies using psychological versus pill placebo was found for either controlled or pre-post placebo effect sizes, the lack of complete uniformity in control conditions limits the precision of the comparison. For instance, studies using pill placebo typically do not control the time spent with a clinician and may attract a unique sample that is open to both pharmacological and psychotherapy treatments. In studies using psychological placebos, on the other hand, providers and even patients may know that they are assigned to a control condition. In addition, there was some variability in the form and content of psychological placebo treatments across studies, and it is possible that this affected the relative effects of CBT seen in different studies. While not considered a true placebo condition for the purposes of this study, future research would also benefit from comparing full treatment to minimally instructed self-guided CBT.
Despite these limitations, the present results provide strong evidence that CBT is an efficacious treatment for anxiety and related disorders in adults, and that its effects meaningfully exceed that of placebo. In addition, the impact of CBT extends beyond the symptoms of the disorder being targeted, and lasts beyond acute treatment. Results also suggest room for improvement, especially for
